Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism

REFERENCES

• van Keep P A. The turbulent history of oral contraception. The Pill, the Most Misunderstood Drug in the World, G Samsioe. Parthenon Publishing, Carnforth, UK 1991; 11–20
   Google Scholar
• Rekers H, Norpoth T, Michaels M A. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies. Eur J Contracept Reprod Health Care 1996; 1: 21–30
   PubMedGoogle Scholar
• WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–8
   PubMed Web of Science ®Google Scholar
• Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93
   PubMed Web of Science ®Google Scholar
• Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Büller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593–6
   PubMed Web of Science ®Google Scholar
• Spitzer W O, Lewis M A, Heinemann L AJ, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83–8
   PubMed Web of Science ®Google Scholar
• Newton J R. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995; 1: 231–63
   PubMed Web of Science ®Google Scholar
• Guillebaud J. Contraception, Your Questions Answered, 2nd ed. Churchill Livingstone, Edinburgh 1993
   Google Scholar
• Lis Y, Spitzer W, Mann R D, et al. A concurrent cohort study of oral contraceptive users from the VAMP research bank. Pharmacoepidemiol Drug Saf 1993; 2: 51–63
   Google Scholar
• Poulter N R, Farley T MM, Chang C L, Marmot M G, Meirik O. Safety of combined oral contraceptive pills. Lancet 1996; 347: 547
   Google Scholar
• Heinemann L AJ, Lewis M A, Assmann A, Gravens L, Guggenmoos-Holzmann I. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?. Pharmacoepidemiol Drug Saf 1996; 5: 285–94
   PubMedGoogle Scholar
• Farmer R DT, Lawrenson R. Utilisation patterns of oral contraceptives in UK general practice. Contraception 1996; 53: 211–15
   PubMed Web of Science ®Google Scholar
• van Lunsen H W. Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third generation progestogens. Eur J Contracept Reprod Health Care 1996; 1: 39–45
   PubMedGoogle Scholar
• Jamin C, De Mouzon J. Selective prescribing of third generation oral contraceptives (OCs). Contraception 1996; 54: 55–6
   PubMed Web of Science ®Google Scholar
• Lewis M A, Heinemann L AJ, MacRae K D, Bruppacher R, Spitzer W O. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5–13
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Lawrenson R A, Thompson C R, Kennedy J G, Hambleton I R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83–8
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand 1997; 76: 252–60
   PubMed Web of Science ®Google Scholar
• Lewis M A. The epidemiology of oral contraceptive use: a critical review of studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179: 1086–97
   PubMed Web of Science ®Google Scholar
• IFFS. Consensus conference on combination oral contraceptives and cardiovascular disease. Fertil Steril 1999; 71: 1S–6S
   PubMed Web of Science ®Google Scholar
• Todd J C, Lawrenson R, Farmer R DT, Williams T J, Leydon G M. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the Medi Plus database. Hum Reprod 1999; 14: 1500–5
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Todd J C, Lewis M A, MacRae K D, Williams T J. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57: 67–70
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Lawrenson R A, Todd J C, Williams T J, MacRae K D. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Medi Plus Database. Hum Reprod Update 1999; 5: 688–706
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. Contraception 1998; 57: 291–301
   PubMed Web of Science ®Google Scholar
• Suissa S, Blais L, Spitzer W O, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–6
   PubMed Web of Science ®Google Scholar
• Suissa S. New analyses of the Transnational study data: the risk of venous thromboembolism among repeat users and switchers of newer oral contraceptives. Hum Reprod 2000, in press
   PubMed Web of Science ®Google Scholar
• Lewis M A, MacRae K D, Kuhl-Habich D, Bruppacher R, Heinemann L AJ, Spitzer W O. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493–9
   PubMed Web of Science ®Google Scholar
• Bloemenkamp K WM, Rosendaal F R, Büller H R, Helmerhorst F M, Colly L P, Vandenbroucke J P. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65–70
   PubMed Web of Science ®Google Scholar
• Herings R MC, Urquhart J, Leufkens H GM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127–8
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K WM, Rosendaal F R. Third-generation oral contraceptives and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177: 887–91
   PubMed Web of Science ®Google Scholar
• Walker A M. Newer oral contraceptives and the risk of thromboembolism. Contraception 1998; 57: 169–81
   PubMed Web of Science ®Google Scholar
• Jick H, Jick S S, Myers M W, Vasilakis C. Third generation oral contraceptives and venous thrombosis. Lancet 1997; 349: 732–3
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K W, Rosendaal F R. Third generation oral contraceptives and venous thrombosis. Lancet 1997; 349: 731
   PubMedGoogle Scholar
• Poulter N R, Chang C L, Marmot M, Farley T M, Meirik O. Third generation oral contraceptives and venous thrombosis. Lancet 1997; 349: 732
   PubMed Web of Science ®Google Scholar
• Weiss N S. Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives. Contraception 1997; 55: 189–90
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J P, Bloemenkamp K WM, Helmerhorst F H, Rosendaal F R. Risk of oral contraceptives and recency of market introduction. Contraception 1997; 55: 191–2
   PubMed Web of Science ®Google Scholar
• Farley T MM, Meirik O, Marmot M G, Chang C L, Poulter N R. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception 1998; 57: 61–5
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Lawrenson R A. Third generation oral contraceptives and venous thrombosis. Lancet 1997; 349: 733
   PubMed Web of Science ®Google Scholar
• Vasilakis C, Jick S S, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79–83
   PubMed Web of Science ®Google Scholar
• Lewis M A, Spitzer W O. The role of bias in observational studies on oral contraceptives. Contraception 1997; 55: 192–4
   Web of Science ®Google Scholar
• Suissa S, Spitzer W O. Methodologic limitations in comparing the risks of newer oral contraceptives. Contraception 1998; 57: 64–5
   Web of Science ®Google Scholar
• Villa P, Aznar J, Mira Y, Fernandez M A, Vaya A. Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis. Lancet 1996; 347: 397
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Amiral J, Guize L, Scarabin P Y. Safety of combined oral contraceptive pills. Lancet 1996; 347: 549
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J P, Rosendaal F R. End of the line for ‘third-generation-pill’ controversy?. Lancet 1997; 349: 1113–14
   PubMed Web of Science ®Google Scholar
• Bertina R M. Molecular risk factors for thrombosis. Thromb Haemost 1999; 82: 601–9
   PubMed Web of Science ®Google Scholar
• Koster T, Rosendaal F R, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756–61
   PubMed Web of Science ®Google Scholar
• Faioni E M, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci P M. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997; 78: 1343–6
   PubMed Web of Science ®Google Scholar
• Liberti G, Bertina R M, Rosendaal F R. Hormonal state rather than age influenced the cut-off values of protein S. Re-evaluation of the thrombotic risk associated with protein S deficiency in the Leiden Thrombophilia study. Thromb Haemost 1999, Suppl: 214–15
   PubMedGoogle Scholar
• Folsom A R, Wu K K, Shahar E, Davis C E. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829–36
   PubMed Web of Science ®Google Scholar
• Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Arterioscler Thromb 1994; 14: 54–9
   PubMed Web of Science ®Google Scholar
• Meade T W, Brzovic M, Chakrabarti R R, et al. Haemostatic function and ischaemic heart disease: principal results of the North wick Park Heart study. Lancet 1986; 2: 533–7
   PubMed Web of Science ®Google Scholar
• Ruddock V, Meade T W. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJ Med 1994; 87: 403–6
   Google Scholar
• Koster T, Rosendaal F R, Reitsma P H, Velden P A, van der, Briët E, Vandenbroucke J P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719–22
   PubMed Web of Science ®Google Scholar
• Janssen M CH, Verbruggen B W, Hark P JC, Novakova I RO. Factor VIIa determination compared to D-dimer in diagnosis of DVT. Thromb Res 1997; 86: 423–6
   PubMed Web of Science ®Google Scholar
• Rosing J, Tains G, Thomasson M C, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233–8
   PubMed Web of Science ®Google Scholar
• Schramm W, Heinemann L AJ. Oral contraceptives and venous thromboembolism: acquired APC resistance?. Br J Haematol 1997; 98: 491–2
   PubMedGoogle Scholar
• Curvers J, Thomassen M C, Nicolaes G A, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88–94
   PubMed Web of Science ®Google Scholar
• Tans G, Rosendaal F R, Curvers J, Thomassen M, Bertina R M, Rosing J. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999, Suppl: 202–3
   Google Scholar
• Heinemann L AJ, Assmann A, Spannagl M, et al. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 1998; 58: 321–2
   PubMed Web of Science ®Google Scholar
• Visser M CH, de Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271–6
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J P, Bloemenkamp K WM, Helmerhorst F M, Rosendaal F R. Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet 1996; 348: 401–2
   PubMed Web of Science ®Google Scholar
• Thomas S HL. Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales. Lancet 1996; 348: 401
   PubMed Web of Science ®Google Scholar
• van Lunsen H. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996; 348: 1095–6
   PubMedGoogle Scholar
• Cohen J. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996; 348: 1096
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Lewis M A. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996; 348: 1096–7
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Newson R B, MacRae K, Lawrenson R A, Tyrer F. Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives. JE pidemiol Commun Health 1997; 51: 630–5
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Sorensen H T, Dreyer L, Olsen J, Olsen J H. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977–95. Br Med J 1999; 319: 820–1
   PubMed Web of Science ®Google Scholar
• Andersen B S, Steffensen F H, Sorensen H T, Nielsen G L, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium - an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998; 77: 170–3
   PubMed Web of Science ®Google Scholar
• Wiholm B E, Olsson S, Moore N, Wood S. Spontaneous reporting systems outside the United States. Pharmacoepidemiology, B L Strom. John Wiley & Sons, Chichester, UK 1994; 139–56
   Google Scholar
• Office for National Statistics. Legal abortions, June quarter 1996. London, 1997, ONS Monitor AB 97/1
   Google Scholar
• Skjeldestad F E. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997; 55: 11–14
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt. Ergebnisse der Schwanger-schaftsabbruchstatistik nach der gesetzlichen Neure-gelung der Statistik für das Jahr 1996, Wiesbaden, 23 May, 1997
   Google Scholar